Head of Pharma & Biotech — USA (CSO-level mandate)

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CSO leadership mandate anchored in USA. The remit explicitly spans Middle East, India, Australia.

This is a sector or practice-head mandate combining deep domain credibility with commercial ownership of a vertical P&L or global practice line.

You will be measured on outcomes that compound: talent depth, customer trust, and a balance sheet that can flex through cycles.

Context you will inherit

• Market & sector: Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
• Geographic spine: Primary hub USA with explicit corridor responsibility across Middle East, India, Australia.
• Organisation stage: Customer concentration in a handful of strategic accounts shapes both opportunity and reputational risk.
• Stakeholders: Key interfaces include headquarters strategy, regional risk and legal, local regulators (where material), and anchor channel partners.
• Secondary lens: R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership

The mandate (12–24 month arc)

1. Strategic resource allocation: Shift Opex and capex toward bets with highest risk-adjusted return.
2. Discontinuities: Monitor technology and business model shifts that could obsolete current advantages.
3. Customer futures: Scenario plans for how buyer behaviour evolves — especially in B2B services.
4. Exit options: For weak units, define paths (fix, sell, close) with timelines — stop infinite turnaround.
5. Strategic partnerships: Governance that prevents partners from capturing too much of the upside.
6. Metrics hygiene: Strategy scorecard linked to incentives — not a parallel slide deck no one owns.

Responsibilities (representative)

• Challenge business unit strategies for overlap and capital inefficiency.
• Align innovation portfolio with enterprise bets — kill projects that drift.
• Sequence geographic or segment expansion with realistic operating assumptions.
• Integrate ESG into strategy where material to licence to operate and growth.
• Build strategy team talent — mix of analytics, finance, and industry depth.

Leadership profile

• Communication: Executive presence in English; additional languages valued where market-relevant.
• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Deal or transformation fluency: M&A, portfolio moves, or major change programmes in Pharmaceuticals & Biotechnology.
• Geographic muscle: Comfort operating from USA with regular engagement across Middle East, India.

Team & culture

Inclusion and psychological safety are not separate programmes — they are prerequisites for honest debate on strategy and risk. Model curiosity, direct feedback, and consequences for conduct lapses.

Success measures (examples)

• Growth quality: Mix of recurring revenue, new logos, and cross-sell — not volume for its own sake.
• Productivity: Unit cost, automation savings, or throughput improvements with audited baselines.
• Customer: NPS / CSAT where tracked; contract renewals; reference-ability in strategic accounts.
• Franchise: Clean compliance record; reputation stability in industry and government forums.

First 90 days (orientation arc)

• Days 1–30: Listening tour — customers, regulators (as appropriate), top team 1:1s, and unfiltered view of numbers; pause major reorganisation.
• Days 30–60: Publish a short memo on priorities, non-goals, and decision rights; align executive committee on three enterprise bets.
• Days 60–90: Lock operating cadence; fill or upgrade one to two critical seats; deliver one visible win (customer, cost, or culture).
• Commission a pragmatic view of data, cyber, and automation posture; sponsor one bounded pilot with ROI hypothesis.
• Establish escalation discipline with matrix partners — fewer meetings, clearer decision logs.

Stakeholder map (illustrative)

• Internal: CEO or regional president, CFO, risk / legal, CHRO, CIO or CDO, business GMs, internal audit.
• External: Strategic accounts, channel partners, industry associations, regulators (where material).
• Owners: PE operating partners, promoter office, or public investors — pace and clarity matter as much as vision.

Travel & mobility

Multi-hub rhythm — plan for weekly or bi-weekly cross-border travel during integration or transformation peaks.

Compensation

Market-aligned CSO remuneration in Pharmaceuticals & Biotechnology with performance linkage; sign-on and relocation considered for exceptional fits.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and USA. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CSO · USA · Gladwin International Leadership Advisors